In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 679 ( 2023-01-18)
Abstract:
Despite the success of vaccines and early antivirals in combating the ongoing SARS-CoV-2 pandemic, there remains room for improvement. Here, Sasaki et al. tested the ability of a main protease (M pro ) inhibitor, S-217622 (ensitrelvir), to protect hamsters from disease after SARS-CoV-2 infection. The authors found that S-217622 retained activity against the M pro of multiple strains of the virus and reduced disease severity in hamsters when administered orally as a prophylactic or as a therapeutic. Hamsters treated prophylactically with S-217622 did not spread virus to cohoused hamsters. These results support further development of S-217622, which is now under evaluation in a phase 3 clinical trial.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abq4064
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Permalink